CD20-negative

Loss of CD20 Expression in Follicular Lymphoma after Program Anti-Tumor Therapy Including Rituximab: Literature Data and Case Report

LYMPHOID TUMORS , ,

OM Volodina, NA Kupryshina, NA Falaleeva, VA Doronin, AV Mozhenkova, MA Frenkel’, EN Sorokin, NV Kokosadze, NN Tupitsyn, GS Tumyan, EA Osmanov

NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

For correspondence: Ol’ga Mikhailovna Volodina, post-graduate student, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; Tel: +7(499)324-28-54; e-mail: volodi.olga2012@yandex.ru.

For citation: Volodina OM, Kupryshina NA, Falaleeva NA, et al. Loss of CD20 Expression in Follicular Lymphoma after Program Anti-Tumor Therapy Including Rituximab: Literature Data and Case Report. Clinical oncohematology. 2017;10(2):176–81 (In Russ).

DOI: 10.21320/2500-2139-2017-10-2-176-181

ABSTRACT

It is the first description of a case of follicular lymphoma with a loss of CD20 antigen expression during the anti-tumor treatment including rituximab in the NN Blokhin Russian Cancer Research Center. The article discusses the tactics of further management of such patients and the effect of the CD20-negative status of follicular lymphoma tumor cells acquired during immunochemotherapy.

Keywords: follicular lymphoma, CD20-negative, rituximab.

Received: November 18, 2016

Accepted: February 2, 2017

Read in PDF (RUS)pdficon

REFERENCES

  1. Singh V, Gupta D, Almasan A. Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. J Cancer Sci Ther. 2015;7(11):347–58. doi: 10.4172/1948-5956.1000373.
  2. Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood. 2011;117(11):2993–3001. doi: 10.1182/blood-2010-07-298356.
  3. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91. doi: 10.1016/S1470-2045(06)70664-7.
  4. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13):4824–31. doi: 10.1182/blood-2008-04-153189.
  5. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–32. doi: 10.1182/blood-2005-01-0016.
  6. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986–92. doi: 10.1200/JCO.2006.06.4618.
  7. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579–86. doi: 10.1200/JCO.2007.13.5376.
  8. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma gene. Blood. 2002;99(3):754–8. doi: 10.1182/blood.V99.3.754.
  9. Van Meerten T, Van Rijn RS, Hol S, et al. Complement-induced cell death by rituximab depends on D20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006;12(13):4027–35. doi: 10.1158/1078-0432.CCR-06-0066.
  10. Dayde D, Ternant D, Ohresser M, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113(16):3765–72. doi: 10.1182/blood-2008-08-175125.
  11. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359–68. doi: 10.1038/sj.onc.1206939.
  12. Ferreri AJ, Dognini GP, Verona C, et al. Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. Haematologica. 2007;92(1):e1–2. doi: 10.3324/haematol.10255.
  13. Clarke LE, Bayerl MG, Ehmann WC, Helm KF. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. J Cutan Pathol. 2003;30(7):459–62. doi: 10.1034/j.1600-0560.2003.00078.x.
  14. Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113(20):4885–93. doi: 10.1182/blood-2008-08-175208.
  15. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5(3):611–5.
  16. Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, et al. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol. 2003;82(9):585–8. doi: 10.1007/s00277-003-0694-1.
  17. Matsuda I, Hirota S. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma. Int J Clin Exp Pathol. 2015;8(8):9737–41.
  18. Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin’s lymphoma: a retrospective review. Br J Haematol. 2002;119(2):412–6. doi: 10.1046/j.1365-2141.2002.03843.x.